

REMARKS

Status of the Claims

Claims 1, 2, 5-9, 14 and 15 are pending.

Claims 3-4, 10, 12-13 and 16-20 have been cancelled.

Amendments

Claim 1 was amended, at the last line thereof, to insert the list of “aP2 inhibitors” taught in canceled claim 11.

Claim 14 was amended, at line 1 thereof, to be an independent claim; and on the last line thereof, to remove the semicolon preceding the period.

Applicants believe that the present amendments do not introduce new matter and do not broaden the scope of the claims.

Rejections Under 35 U.S.C. § 102(b)

Claims 1, 2 and 5-9 were rejected under 35 U.S.C. § 102(b) as being allegedly anticipated by Meguro et al. (U.S. Pat. # 4,687,777) and Sandouk et al. Applicants have hereby amended claim 1 to include the limitations of allowed claim 11. Thus, the teachings of amended claim 1 and the claims depending therefrom should not be anticipated by the disclosure of the ‘777 patent and the Sandouk et al. reference. Consequently, this rejection should now be obviated and kindly removed.

Allowed Claims

Claims 11, 14 and 15 are deemed allowable.

SUMMARY

In view of the foregoing, it is requested that this case proceed to issuance. The Examiner is invited to contact the undersigned if it is believed prosecution could be expedited.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
609-252-4931

/joseph c wang/
Joseph C. Wang
Attorney for Applicants
Reg. No. 44,391

Date: February 28, 2007